ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

International Journal of Cancer

Volumn 94, Issue 6, 2001, Pages 774-782

  Anderson, Neil G ^a   Ahmad, Tawhid ^a   Chan, Kai ^a   Dobson, Richard ^a   Bundred, Nigel J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antiproliferative; Epidermal growth factor receptor; erbB2; Tyrosine kinase inhibitor; ZD1839

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT; VULVA CARCINOMA;

CELL DIVISION; EPIDERMAL GROWTH FACTOR; GENES, ERBB-2; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0035892346     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1557     Document Type: Article

References (45)

1. The ErbB signaling network: Receptor heterodimerization in development and cancer
2. Epidermal growth factor-related peptides and their receptors in human malignancies
3. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors
4. Multiple positive and negative regulators of signaling by the EGF-receptor
5. Erb-B2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signalling
6. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
7. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases
8. The neu-oncogene: Signal transduction pathways, transformation mechanisms and evolving therapies
9. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells
10. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
11. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
12. Anticancer drug targets: Growth factors and growth factor signaling
13. Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ
14. Preclinical studies with the oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 ("Iressa"), demonstrate significant anti-tumour activity
15. Epidermal growth factor receptor gene expression in estrogen receptor-positive and -negative human breast cancer cell lines
16. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor
17. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity
18. Requirement for phospholipase C-γ1 enzymatic activity in growth factor-induced mitogenesis
19. Mechanisms and consequences of activation of protein kinase B/Akt
20. Cellular stresses can modulate the sensitivity of human carcinoma cells to EGFR kinase inhibitors
21. Growth inhibition of tumour cells by epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is associated with upregulation of p27 and p21 cyclin-dependent kinase inhibitors
22. Antitumour effects and potentiation of cytotoxic drug activity in human cancer cell lines by ZD-1839 (Iressa), an EGFR-specific tyrosine kinase inhibitor
23. ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Inhibition of c-fos mRNA, an immediate marker of EGFR activation, correlates with tumour growth inhibition
24. Potentiation of cytotoxic agents against human tumours in mice by ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR
25. Cyclin D1 expression is regulated positively by the p42/p44 MAP kinase and negatively by the p38/HOG pathway
26. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)
27. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway
28. Hyperexpression of mitogen-activated protein kinase in human breast cancer
29. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines
30. Activation of mitogen-activated protein kinase associated with prostate cancer progression
31. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
32. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
33. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells
34. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
35. Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor
36. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development
37. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity
38. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation
39. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
40. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism
41. Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo
42. Oncogenic Ha-Ras-dependent mitogen-activated protein kinase activity requires signaling through the epidermal growth factor receptor
43. ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation
44. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins
45. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines